Orvana Minerals' Bolivian subsidiary, EMIPA, has extended the maturity date of its $25 million secured prepayment facility with Trafigura by six months, moving it from December 2026 to June 2027. This adjustment aligns the repayment schedule with the production ramp-up of the Don Mario Oxides Stockpile Project. The extension provides EMIPA more time to meet its financial obligations as the project scales up copper cathode and gold-silver doré production. The company remains cautious about risks including production delays, metal price fluctuations, and operational costs but expects the ramp-up to proceed as planned.
Orvana Minerals' prepayment facility amendment is the subject, with Pluang market data as context. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 03, 2026 06:12 WIB: of 38 priced US stocks, 16 rose and 20 fell. Notable movers include WPM at USD 136.00 with 0% Sell / 100% Buy order activity, NUE at USD 240.38 also with 0% Sell / 100% Buy, and MP at USD 46.92 with 12% Sell / 88% Buy. The most notable figure is WPM's 100% Buy order activity.
OKB token traded around $120.25 with minimal weekly price change, reflecting a quiet market. The key development is a nearly 10% drop in deposits on X Layer, the Ethereum scaling chain powered by OKB, falling from $186.9 million to $168.3 million sin...
The U.S. Securities and Exchange Commission (SEC) has reportedly approved the first 3x leveraged Bitcoin and Ethereum exchange-traded funds (ETFs) for listing and trading on a U.S. exchange, marking the highest leverage ratio cleared for crypto ETFs ...
Starz Entertainment (STRZ) has achieved over 100% gains year-to-date, supported by improving business fundamentals and attractive valuation. The company recently raised its full-year earnings guidance and committed to deleveraging its balance sheet, ...
Shiba Inu (SHIB) saw a net burn of about 20 billion tokens in the past 24 hours, reflecting modest exchange activity despite a recovering price. The token price has improved since summer lows, currently trading near $0.00000592, and is above a key lo...
Ardent Health's stock is considered undervalued and a 'buy' despite recent declines in profitability. The company’s revenue is growing, with management forecasting $6.4 to $6.7 billion for the year, though EBITDA and cash flow are expected to be lowe...
